Post-earnings recap
Reported
Tue, May 6, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Arrowhead Pharmaceuticals is facing significant challenges, particularly reflected in their EPS miss. The stock dropped 6.75% following the announcement, likely due to investor disappointment over the lack of revenue details and guidance. The management's defensive tone suggests they are aware of the hurdles ahead but remain focused on future improvements.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | -69.40% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concern over recent performance but highlighted their commitment to long-term goals. They are actively working to address the issues that impacted results.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
There was a focus on future product development despite current setbacks.